Abpro (ABP) Competitors $0.22 -0.03 (-12.24%) As of 09/5/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock ABP vs. CNTX, CVM, IGMS, UNCY, INCR, ASRT, PMVP, OSTX, APLT, and ELYMShould you be buying Abpro stock or one of its competitors? The main competitors of Abpro include Context Therapeutics (CNTX), CEL-SCI (CVM), IGM Biosciences (IGMS), Unicycive Therapeutics (UNCY), InterCure (INCR), Assertio (ASRT), PMV Pharmaceuticals (PMVP), OS Therapies (OSTX), Applied Therapeutics (APLT), and Eliem Therapeutics (ELYM). These companies are all part of the "pharmaceutical products" industry. Abpro vs. Its Competitors Context Therapeutics CEL-SCI IGM Biosciences Unicycive Therapeutics InterCure Assertio PMV Pharmaceuticals OS Therapies Applied Therapeutics Eliem Therapeutics Abpro (NASDAQ:ABP) and Context Therapeutics (NASDAQ:CNTX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and media sentiment. Do analysts rate ABP or CNTX? Abpro currently has a consensus price target of $4.00, indicating a potential upside of 1,760.47%. Context Therapeutics has a consensus price target of $5.25, indicating a potential upside of 539.93%. Given Abpro's higher possible upside, analysts plainly believe Abpro is more favorable than Context Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Abpro 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Context Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 Do institutionals and insiders believe in ABP or CNTX? 23.3% of Abpro shares are owned by institutional investors. Comparatively, 14.0% of Context Therapeutics shares are owned by institutional investors. 20.8% of Abpro shares are owned by company insiders. Comparatively, 2.8% of Context Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the media refer more to ABP or CNTX? In the previous week, Context Therapeutics had 2 more articles in the media than Abpro. MarketBeat recorded 2 mentions for Context Therapeutics and 0 mentions for Abpro. Context Therapeutics' average media sentiment score of 1.33 beat Abpro's score of 0.00 indicating that Context Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Abpro Neutral Context Therapeutics Positive Is ABP or CNTX more profitable? Abpro's return on equity of 0.00% beat Context Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets AbproN/A N/A -241.16% Context Therapeutics N/A -38.80%-37.53% Which has more risk and volatility, ABP or CNTX? Abpro has a beta of 0.03, indicating that its share price is 97% less volatile than the S&P 500. Comparatively, Context Therapeutics has a beta of 1.91, indicating that its share price is 91% more volatile than the S&P 500. Which has preferable earnings and valuation, ABP or CNTX? Abpro has higher revenue and earnings than Context Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAbpro$180K95.76-$7.23MN/AN/AContext TherapeuticsN/AN/A-$26.73M-$0.36-2.28 SummaryContext Therapeutics beats Abpro on 7 of the 13 factors compared between the two stocks. Get Abpro News Delivered to You Automatically Sign up to receive the latest news and ratings for ABP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ABP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ABP vs. The Competition Export to ExcelMetricAbproMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$17.24M$3.18B$5.83B$9.93BDividend YieldN/A2.27%6.70%4.52%P/E RatioN/A21.1076.1526.11Price / Sales95.76466.44562.61123.62Price / CashN/A45.7236.9959.28Price / Book-0.749.8711.486.09Net Income-$7.23M-$53.42M$3.29B$266.51M7 Day Performance-12.28%2.93%1.27%0.46%1 Month Performance-16.80%9.85%7.94%4.59%1 Year PerformanceN/A15.74%62.94%26.04% Abpro Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ABPAbproN/A$0.22-12.2%$4.00+1,760.5%N/A$17.24M$180K0.0015Gap DownCNTXContext Therapeutics3.4155 of 5 stars$0.90+2.8%$5.25+485.3%-64.0%$78.30MN/A-2.397Positive NewsCVMCEL-SCI0.3058 of 5 stars$11.30+7.0%N/A-68.2%$77.77MN/A-23.5443Negative NewsShort Interest ↑IGMSIGM Biosciences4.0889 of 5 stars$1.27flat$5.50+333.1%N/A$76.57M$145.05M-1.41190UNCYUnicycive Therapeutics3.0586 of 5 stars$4.24-1.3%$60.00+1,316.8%+23.4%$75.77MN/A-1.039News CoverageGap DownINCRInterCure0.2226 of 5 stars$1.66-0.3%N/A-22.9%$75.65M$238.85M0.00350Positive NewsASRTAssertio1.778 of 5 stars$0.78-0.7%$2.38+204.5%-37.2%$75.61M$124.96M-1.7420Gap DownPMVPPMV Pharmaceuticals2.5141 of 5 stars$1.44+1.4%$5.50+281.9%-4.6%$75.25MN/A-0.9250Gap UpHigh Trading VolumeOSTXOS Therapies2.0604 of 5 stars$2.33+6.4%$18.00+672.5%-45.0%$74.31MN/A-2.95N/AAnalyst ForecastAPLTApplied Therapeutics4.2125 of 5 stars$0.53+2.0%$6.10+1,061.9%-91.9%$74.09M$460K-1.1930Positive NewsGap UpELYMEliem TherapeuticsN/A$2.48+4.2%N/A-69.2%$73.79MN/A-4.689Gap UpHigh Trading Volume Related Companies and Tools Related Companies CNTX Alternatives CVM Alternatives IGMS Alternatives UNCY Alternatives INCR Alternatives ASRT Alternatives PMVP Alternatives OSTX Alternatives APLT Alternatives ELYM Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ABP) was last updated on 9/6/2025 by MarketBeat.com Staff From Our PartnersScientists Discover Untapped Energy Source in Heart of USACrash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | Sponsored6-Figure Target for BTC by 2025Crypto ETF records broken – here's what’s next The biggest names in finance have built the infrastructure f...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored3 Major A.I. Threats That Could Upend the U.S. EconomyThe media's calling Artificial Intelligence a "revolution," but for many Americans, the real impact might actu...Goldco Precious Metals | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredDid you spot this in the Oval Office last week?When Tim Cook stood in the Oval Office last week, all eyes were on the "unique 24K gold gift" he presented to ...InvestorPlace | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Abpro Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Abpro With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
